No abstract available
Keywords:
AHA Scientific Statements; Guidelines; biomarkers, coronary artery calcium score; cardiovascular disease; cholesterol, LDL-cholesterol; diabetes mellitus; drug therapy; ezetimibe; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; pharmacological; primary prevention; proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors; risk assessment; risk reduction discussion; risk treatment discussion, secondary prevention.
Publication types
-
Practice Guideline
-
Systematic Review
MeSH terms
-
Anticholesteremic Agents / adverse effects
-
Anticholesteremic Agents / therapeutic use*
-
Biomarkers / blood
-
Cardiology / standards*
-
Cardiovascular Diseases / blood
-
Cardiovascular Diseases / diagnosis
-
Cardiovascular Diseases / epidemiology
-
Cardiovascular Diseases / prevention & control*
-
Cholesterol / blood*
-
Consensus
-
Evidence-Based Medicine / standards*
-
Humans
-
Hyperlipidemias / blood
-
Hyperlipidemias / diagnosis
-
Hyperlipidemias / drug therapy*
-
Hyperlipidemias / epidemiology
-
Risk Assessment
-
Risk Factors
-
Treatment Outcome
Substances
-
Anticholesteremic Agents
-
Biomarkers
-
Cholesterol